The endocannabinoid system: a promising novel mechanistic pathway in the cardiometabolic syndrome.
The endocannabinoid system (ECS) is a neuroendocrine system that modulates several cardiometabolic processes. An overactive ECS is implicated as a significant contributor to the cardiometabolic syndrome and obesity, in addition to a large number of other physiologic processes. Endocannabinoid receptors have been detected centrally and peripherally, regulating appetite, food intake, metabolism, and storage. ECS blockade is thought to be a promising new pharmacologic modality of improving the unfavorable metabolic risk profile in patients with the cardiometabolic syndrome and obesity.
Al-Jaghbeer
Eshraq
E
Department of Internal Medicine, Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL 600064, USA.
Khraisat
Ahmad
A
Singh
Sant P
SP
D000273:Adipose Tissue / Q000378:metabolism; D001069:Appetite Regulation / Q000502:physiology; D063385:Cannabinoid Receptor Modulators / Q000037:antagonists & inhibitors / Q000378:metabolism*; D063388:Endocannabinoids; D004734:Energy Metabolism / Q000187:drug effects / Q000502:physiology; D006801:Humans; D024821:Metabolic Syndrome / Q000378:metabolism* / Q000628:therapy*; D015398:Signal Transduction
D063385:Cannabinoid Receptor Modulators; D063388:Endocannabinoids